Delayed
TEL AVIV STOCK EXCHANGE
06:29:08 2024-05-21 am EDT
|
5-day change
|
1st Jan Change
|
1,954
ILa
|
-1.41%
|
|
-5.15%
|
-12.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
960.1
|
924.6
|
920.4
|
615
|
1,280
|
1,139
|
-
|
-
|
Enterprise Value (EV)
1 |
960.1
|
924.6
|
920.4
|
615
|
1,280
|
1,139
|
1,139
|
1,139
|
P/E ratio
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.2
x
|
2.13
x
|
2.7
x
|
1.31
x
|
2.51
x
|
1.94
x
|
1.71
x
|
1.48
x
|
EV / Revenue
|
2.2
x
|
2.13
x
|
2.7
x
|
1.31
x
|
2.51
x
|
1.94
x
|
1.71
x
|
1.48
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
14,821,198
x
|
-
|
-
|
-
|
EV / FCF
|
11.5
x
|
22.5
x
|
-22.1
x
|
-
|
-233
x
|
16.2
x
|
12
x
|
8.27
x
|
FCF Yield
|
8.72%
|
4.44%
|
-4.52%
|
-
|
-0.43%
|
6.16%
|
8.37%
|
12.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,512
|
44,731
|
44,786
|
44,826
|
57,476
|
57,480
|
-
|
-
|
Reference price
2 |
23.70
|
20.67
|
20.55
|
13.72
|
22.27
|
19.82
|
19.82
|
19.82
|
Announcement Date
|
2/12/20
|
2/10/21
|
3/15/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
436.2
|
433.1
|
340.3
|
469.1
|
510.9
|
587.4
|
664.3
|
772.4
|
EBITDA
|
-
|
-
|
-
|
-
|
86.36
|
-
|
-
|
-
|
EBIT
1 |
78.14
|
62.53
|
-2.286
|
16.44
|
36.08
|
75.71
|
81.38
|
114
|
Operating Margin
|
17.91%
|
14.44%
|
-0.67%
|
3.5%
|
7.06%
|
12.89%
|
12.25%
|
14.75%
|
Earnings before Tax (EBT)
1 |
78.81
|
60.35
|
-6.19
|
-8.192
|
30.22
|
69.75
|
77.9
|
110.1
|
Net income
1 |
76.31
|
55.72
|
-7.323
|
-8.417
|
29.7
|
55.1
|
66.75
|
93.97
|
Net margin
|
17.49%
|
12.86%
|
-2.15%
|
-1.79%
|
5.81%
|
9.38%
|
10.05%
|
12.17%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
83.7
|
41.06
|
-41.62
|
-
|
-5.499
|
70.22
|
95.3
|
137.8
|
FCF margin
|
19.19%
|
9.48%
|
-12.23%
|
-
|
-1.08%
|
11.95%
|
14.35%
|
17.84%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
109.69%
|
73.69%
|
-
|
-
|
-
|
127.43%
|
142.77%
|
146.64%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/12/20
|
2/10/21
|
3/15/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
103.3
|
95.31
|
76.9
|
111.8
|
164.8
|
113.6
|
140.1
|
146.1
|
130.6
|
140.3
|
144.8
|
147.7
|
154.1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.84
|
0.8346
|
-7.478
|
8.893
|
14.57
|
1.069
|
9.846
|
16.82
|
9.951
|
15.01
|
13.17
|
13.05
|
34.45
|
Operating Margin
|
-10.49%
|
0.88%
|
-9.72%
|
7.95%
|
8.84%
|
0.94%
|
7.03%
|
11.51%
|
7.62%
|
10.7%
|
9.09%
|
8.84%
|
22.36%
|
Earnings before Tax (EBT)
1 |
-15.32
|
-6.063
|
-12.75
|
1.715
|
10.68
|
-6.641
|
7.129
|
12.69
|
18.01
|
9.065
|
13.17
|
13.05
|
34.45
|
Net income
1 |
-16.45
|
-6.202
|
-12.78
|
1.68
|
10.68
|
-6.689
|
6.781
|
12.41
|
18.13
|
8.79
|
10.4
|
10.31
|
27.21
|
Net margin
|
-15.92%
|
-6.51%
|
-16.62%
|
1.5%
|
6.48%
|
-5.89%
|
4.84%
|
8.5%
|
13.88%
|
6.27%
|
7.18%
|
6.98%
|
17.66%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/17/22
|
8/17/22
|
11/22/22
|
3/15/23
|
5/24/23
|
8/16/23
|
11/13/23
|
3/6/24
|
5/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
83.7
|
41.1
|
-41.6
|
-
|
-5.5
|
70.2
|
95.3
|
138
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
7.89
|
17.9
|
12.2
|
13.7
|
21
|
1.81
|
1.45
|
1.15
|
Capex / Sales
|
1.81%
|
4.12%
|
3.59%
|
2.93%
|
4.1%
|
0.31%
|
0.22%
|
0.15%
|
Announcement Date
|
2/12/20
|
2/10/21
|
3/15/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -12.26% | 309M | | -3.15% | 89.69B | | +3.95% | 41.34B | | -10.51% | 33.72B | | +59.13% | 26.11B | | -20.09% | 14.63B | | -8.92% | 12.84B | | -11.46% | 11.66B | | -43.05% | 11.52B | | +4.49% | 8.92B |
Biopharmaceuticals
|